Prescribing information available here
Adverse event reporting information can be found at the bottom of this page
The Bufomix (budesonide/formoterol) Easyhaler® range delivers effective, well-tolerated, and affordable therapy for asthma and COPD care.
The maintenance and reliever therapy indication in asthma for all ages from 12 years allows flexible tailoring of therapy for patients. Bufomix Easyhaler® is certified carbon neutral and produced by Orion Pharma in Finland.1
Bufomix Easyhaler Contraindications and Undesirable effects
Contraindications: Hypersensitivity to the active substances or lactose monohydrate (which contains small amounts of milk protein).
Undesirable effects:
Common (≥1/100 to < 1/10): Candida infections in the oropharynx, pneumonia (in COPD patients) headache, tremor, palpitations, mild irritation in the throat, coughing, dysphonia including hoarseness.
See SmPC for full list of adverse reactions
Date of preparation: October 2024 / EASYH-2728(1)
References
- Budesonide-formoterol Easyhaler 80/4.5, 160/4.5, and 320/9 mcg. SmPC. Orion Pharma.
DATE OF PREPARATION: MAY 2023/EASYH-688(10)
FULL PRESCRIBING INFORMATION AVAILABLE HERE
For more information about Orion and Sustainability click here
| Adverse effects should be reported. You can report side effects directly via the Health Products Regulatory Authority (HPRA) website: www.hpra.ie or by email on medsafety@hpra.ie. Adverse effects should also be reported to Orion Pharma via ie.medicalinformation@orionpharma.com |
